SLV-308. Solvay

Curr Opin Investig Drugs. 2003 Jul;4(7):878-82.

Abstract

Solvay is developing SLV-308 (SME-308), a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties, for the potential oral treatment of Parkinson's disease (PD), panic and depression. By January 2001, SLV-308 had entered phase II trials for PD and phase I trials for anxiety and depression.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / chemical synthesis
  • Antiparkinson Agents / therapeutic use*
  • Benzoxazoles / chemistry
  • Benzoxazoles / therapeutic use
  • Clinical Trials as Topic / statistics & numerical data
  • Drugs, Investigational / chemical synthesis
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Parkinson Disease / drug therapy*
  • Piperazines / chemistry
  • Piperazines / therapeutic use
  • Technology, Pharmaceutical / methods

Substances

  • Antiparkinson Agents
  • Benzoxazoles
  • Drugs, Investigational
  • Piperazines
  • pardoprunox